🇧🇬 2026-11-22 · INSAIT

Aleksandrina Goeva vraća se iz Toronta u Sofiju u potrazi za novim lijekovima s AI

Nakon što je izgradila vlastiti istraživački tim na Sveučilištu u Torontu, dr. Aleksandrina Goeva vraća se u Bugarsku. Na INSAIT-u, Sveučilište u Sofiji, vodit će novi smjer istraživanja. Njezin će tim upotrijebiti AI kako bi predvidio kako bolesne stanice reagiraju na različite spojeve i koje od njih vrijedi testirati kao buduće lijekove.

Illustration: colorful human cells under a microscope, linked by a glowing network of data
AI-generated illustration

The possible combinations are so many that even a well equipped lab can test only a small share of them. Where should scientists start? This is where computer models can help. If they predict which compounds, alone or in combination, would help cells return to normal function, researchers can check the most promising ones first. The team will also study whether changes in cells can signal earlier that a disease is developing.

For Goeva this is also a return to the university where she studied. She graduated from the Sofia High School of Mathematics and then studied applied mathematics at Sofia University. At Boston University she earned a master's in mathematics and a PhD in statistics. She spent seven years at the Broad Institute of MIT and Harvard. Later, in Toronto, she built a team in machine learning and computational biology.

Among her work is the HiDDEN method, described in Nature Communications in 2024. It lets scientists tell cells affected by disease apart from healthy ones in the same sample. With it they noticed cell changes that had been missed in studies of blood cancer and of damage to the protective barrier between the blood and the brain. Goeva has also published in Science, Cell and Nature Biotechnology. According to Google Scholar, her work has been cited more than 7,200 times.

INSAIT announced the new research direction on November 9, 2026. The institute has not said what the budget will be, how many people will work on the team or when results are expected. Between choosing a promising compound and approving it as a medicine lie laboratory studies and clinical trials.

Sources

Told by Aurora, a language model. Every story is reviewed by a person before publication. Translated automatically from the English text.

More stories

Good news on Telegram · Follow

A representative website for your business

GOODNEWS is a project of ECOMM, Ruse, Bulgaria. We build representative websites for companies and for people whose name is their business.

Visit ECOMM

Give someone good news

The name and the words stay in the link only. They never pass through our server.